160 Parallel studies in humans could help form the rational basis for a more unified PD-L1 immunohistochemistry scoring approach. In conclusion, the recent success of immune-based cancer therapy ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

IHC: Immunohistochemistry; NSCLC: Non-small-cell lung cancer. Adapted with permission from [77]. The authors have no relevant affiliations or financial involvement with any organization or entity ...

operable [tumor stage T1 to T3 and nodal stage N0 or ... The 7-year invasive disease–free survival in the IHC 3+ cohorts (total, 1132 patients) was 82.8% with T-DM1 and 66.5% with trastuzumab ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...